| Waksman, Ron |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Coronary Artery Disease | 01/27 | 01/27 | | |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17004 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
| Recruiting | N/A | 1150 | US, RoW | Portico transcatheter aortic valve, Commercially available transcatheter aortic valve | Abbott Medical Devices | Aortic Valve Stenosis | 10/19 | 07/25 | | |
NCT02799823: Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial |
|
|
| Terminated | N/A | 11 | US | HLT Transcatheter Aortic Valve System | HLT Inc. | Aortic Valve Stenosis | 01/23 | 01/23 | | |
NCT03557242: Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement |
|
|
| Active, not recruiting | N/A | 124 | US | TAVR, Warfarin plus Aspirin, Aspirin Only | Medstar Health Research Institute | Aortic Stenosis | 07/23 | 07/23 | | |
CAMEO, NCT04076813: Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry |
|
|
| Recruiting | N/A | 4000 | US | | Chiesi USA, Inc., Duke University | Myocardial Infarction | 10/24 | 10/24 | | |
| Active, not recruiting | N/A | 418 | Europe, Canada, US, RoW | SELUTION SLR™ DEB, Control | M.A. Med Alliance S.A., Iqvia Pty Ltd, Cordis Corporation | Coronary Restenosis | 07/25 | 08/29 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
NCT03002272: Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study |
|
|
| Recruiting | N/A | 100 | US | TAVR, SAVR | Medstar Health Research Institute | Aortic Valve Replacement | 01/24 | 01/28 | | |
| Active, not recruiting | N/A | 25 | US | J-Valve TF System | JC Medical, Inc. | Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation | 07/24 | 08/29 | | |
| Not yet recruiting | N/A | 264 | NA | TAVR-explant, Redo-TAVR, Valve-in-Valve, TAV-in-TAV | Medstar Health Research Institute | Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction, Prosthesis Failure | 05/34 | 05/36 | | |
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial |
|
|
| Active, not recruiting | N/A | 2005 | US | Orbital Atherectomy, Balloon | Abbott Medical Devices, Cardiovascular Research Foundation, New York | Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction | 06/24 | 06/25 | | |
NCT05966662: Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO) |
|
|
| Active, not recruiting | N/A | 145 | US | IVL with Shockwave C2+ 2Hz Coronary IVL Catheter | Shockwave Medical, Inc. | Coronary Artery Disease, Myocardial Infarction | 01/25 | 12/25 | | |
| Recruiting | N/A | 960 | US | PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES | M.A. Med Alliance S.A., NAMSA, Cordis Corporation | Coronary Artery Disease | 08/25 | 08/29 | | |
| Recruiting | N/A | 15 | US | AltaValve | 4C Medical Technologies, Inc. | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence | 09/25 | 09/25 | | |
| Recruiting | N/A | 650 | Europe, Canada, Japan, US, RoW | Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) | Medtronic Cardiovascular | Moderate Aortic Valve Stenosis | 02/26 | 12/34 | | |
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. |
|
|
| Recruiting | N/A | 1056 | Europe, Canada, US | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Medtronic Cardiovascular | Mitral Valve Regurgitation | 10/26 | 09/36 | | |
| Recruiting | N/A | 1000 | Canada, US | | Medstar Health Research Institute | Mitral Valve Disease | 02/27 | 02/27 | | |
| Recruiting | N/A | 1000 | US | Outcomes for Patients with CMD | Medstar Health Research Institute | Coronary Microvascular Dysfunction | 01/33 | 01/33 | | |
| Baran, David A |
| Completed | N/A | 8 | US | JuxtaFlow System | 3ive Labs | Cardiorenal Syndrome | 05/23 | 10/23 | | |
| Recruiting | N/A | 30 | US | Doraya Catheter | Revamp Medical Inc. | Acute Decompensated Heart Failure | 10/25 | 12/25 | | |
| Recruiting | N/A | 50 | US | glecaprevir/pibrentasivir | Sentara Norfolk General Hospital | Coronary Artery Disease, Morality | 12/24 | 12/24 | | |
| Recruiting | N/A | 750 | Europe, Canada, US, RoW | Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) | Corvia Medical | Heart Failure, Heart Failure, Diastolic | 05/25 | 03/31 | | |
| Recruiting | N/A | 500 | Canada, US | | STAVROS G DRAKOS | Cardiogenic Shock, Acute Myocardial Infarction | 12/27 | 12/27 | | |
| O'Brien, Thomas R |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy |
|
|
| Completed | 2 | 190 | Canada, US | SUVN-G3031, Samelisant, Placebo | Suven Life Sciences Limited | Narcolepsy | 06/23 | 06/23 | | |
NCT03563261: Muscle-Tendon Mechanics During Locomotor Tasks, Efficacy of Collagen Supplementation for Older Adults |
|
|
| Completed | N/A | 21 | Europe | Collagen supplement group, Placebo supplement group | Liverpool John Moores University | Tendon Stiffness With Age | 06/21 | 06/21 | | |
| Alloway, Rita |
BETTER, NCT04849533: Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation ( Trial) |
|
|
| Recruiting | 4 | 120 | US | Belatacept, Nulojix, Everolimus, Zortress, mycophenolate mofetil, Cellcept, corticosteroids, Prednisone, rabbit antithymocyte globulin, rATG, thymoglobulin | University of Cincinnati | Kidney Transplant Rejection | 07/23 | 07/24 | | |
| Active, not recruiting | N/A | 1500 | US | LiverCare | CareDx | Liver Transplantation, Biomarkers | 12/27 | 03/28 | | |
| Chung, Gina |
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer |
|
|
| Terminated | 3 | 5 | US | Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus | Veru Inc. | Metastatic Breast Cancer | 10/23 | 01/24 | | |
| Terminated | 3 | 52 | Europe, US, RoW | Enobosarm, VERU-024, Exemestane, Mestane | Veru Inc. | Metastatic Breast Cancer | 01/24 | 01/24 | | |
| Active, not recruiting | 3 | 354 | US | Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac | SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc. | Colorectal Neoplasms | 02/27 | 02/32 | | |
SWOG-S1501, NCT03418961: S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer |
|
|
| Recruiting | 3 | 817 | US, RoW | Carvedilol, Coreg, Laboratory Biomarker Analysis, Patient Observation, Active Surveillance, deferred therapy, expectant management, observation, Watchful Waiting | SWOG Cancer Research Network, National Cancer Institute (NCI) | Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 | 01/30 | 01/30 | | |
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer |
|
|
| Withdrawn | 2 | 200 | US | Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane | Veru Inc. | Metastatic Breast Cancer | 03/24 | 05/24 | | |
NCT03088878: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
|
|
| Completed | 1/2 | 102 | US | Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, UC-961, Imbruvica, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib, Cirmtuzumab (RDR) plus ibrutinib, Cirmtuzumab plus ibrutinib, Ibrutinib alone | Oncternal Therapeutics, Inc, California Institute for Regenerative Medicine (CIRM), University of California, San Diego, Pharmacyclics LLC. | B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | 09/24 | 09/24 | | |
NCT04595838: A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis |
|
|
| Completed | N/A | 176 | US | Chemo Mouthpiece, Oral cryotherapy delivery device, Best Supportive Care only | Chemo Mouthpiece | Oral Mucositis | 05/23 | 05/23 | | |
| Inglessis, Ignacio |
| Recruiting | N/A | 200 | Europe, Canada, US | AVP III | Abbott Medical Devices | Paravalvular Aortic Regurgitation | 07/25 | 06/26 | | |
NCT03735667: ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement |
|
|
| Active, not recruiting | N/A | 1948 | Canada, US | ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL | Boston Scientific Corporation | Aortic Stenosis | 06/24 | 09/34 | | |
| Active, not recruiting | N/A | 1070 | Europe, US | Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure | 06/24 | 12/29 | | |
| Recruiting | N/A | 210 | US | Transseptal ViMAC, ViMAC | Mayra Guerrero | Mitral Annular Calcification, Mitral Stenosis, Mitral Regurgitation, Mitral Valve Disease | 12/24 | 12/24 | | |
| Recruiting | N/A | 870 | Canada, US | Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease | 12/27 | 12/31 | | |
| Terminated | N/A | 7 | US | Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure | W.L.Gore & Associates | Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale | 08/24 | 08/24 | | |
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. |
|
|
| Recruiting | N/A | 1056 | Europe, Canada, US | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Medtronic Cardiovascular | Mitral Valve Regurgitation | 10/26 | 09/36 | | |
REDUCE PAS, NCT03821129: GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study |
|
|
| Recruiting | N/A | 636 | US | PFO closure with GORE® CARDIOFORM Septal Occluder | W.L.Gore & Associates | Stroke, PFO - Patent Foramen Ovale | 12/26 | 12/29 | | |
| Recruiting | N/A | 1000 | Canada, US | | Medstar Health Research Institute | Mitral Valve Disease | 02/27 | 02/27 | | |
| Jaffer, Farouc A |
| Recruiting | N/A | 2000 | Europe, Canada, US, RoW | | Minneapolis Heart Institute Foundation | Coronary Artery Disease | 01/24 | 01/24 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
| Weber, Michael |
| Active, not recruiting | 3 | 300 | US | Dehydrated alcohol, Ethanol, Peregrine System Kit (Sham Procedure) | Ablative Solutions, Inc. | Hypertension | 12/23 | 05/26 | | |
| Active, not recruiting | 3 | 597 | Europe, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 07/25 | 07/25 | | |
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure |
|
|
| Recruiting | 2 | 150 | US | AB-1002, Gene Therapy, NAN-101 | Asklepios Biopharmaceutical, Inc. | Congestive Heart Failure | 10/26 | 12/30 | | |
COMPETENCE, NCT01187368: Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System |
|
|
| Suspended | N/A | 399 | US | EVAHEART Left Ventricular Assist System (LVAS), EVA2, HeartMate 3, HM3 | Evaheart, Inc. | Heart Failure | 07/27 | 07/28 | | |
| Recruiting | N/A | 110 | US, RoW | NEXUS Aortic Stent Graft System | Endospan Ltd. | Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer | 11/24 | 10/29 | | |
| Recruiting | N/A | 960 | Europe, Canada, Japan, US, RoW | | AO Innovation Translation Center, AO Foundation, AO Spine | Metastatic Spine Tumor | 12/25 | 12/25 | | |
NCT05988658: Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients |
|
|
| Recruiting | N/A | 800 | US | ESTOP - AKI 2.0 | University of Chicago, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Wisconsin, Madison | Acute Kidney Injury, Biomarkers | 03/27 | 03/28 | | |
| Williams, Julie A |
ENGOT-EN17, NCT05712941: Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer |
|
|
| Withdrawn | 3 | 320 | NA | Lerociclib, Letrozole 2.5mg, Placebo | EQRx International, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) | Endometrial Carcinoma | 03/24 | 03/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Terminated | 2 | 205 | Europe, US, RoW | ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda | Seagen Inc., Merck Sharp & Dohme LLC | Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma | 11/23 | 11/23 | | |
| Active, not recruiting | 2 | 240 | Europe, US, RoW | CAB-AXL-ADC, BA3011, PD-1 inhibitor | BioAtla, Inc., BioAtla Inc. | Non-Small-Cell Lung Cancer | 08/25 | 08/25 | | |
| Completed | 1/2 | 132 | Europe, US, RoW | CAB-ROR2-ADC, BA3021, PD-1 inhibitor | BioAtla, Inc., BioAtla Inc. | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 10/24 | 09/28 | | |
| Active, not recruiting | N/A | 30 | US | Aliya Pulsed Electric Fields (PEF) | Galvanize Therapeutics, Inc. | Lung Neoplasm Malignant | 08/24 | 07/25 | | |
NCT06004440: Real World Registry for Use of the Ion Endoluminal System |
|
|
| Recruiting | N/A | 3000 | US | Ion Endoluminal System | Intuitive Surgical | Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases | 08/26 | 08/27 | | |
| Miller, Leslie W |
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure |
|
|
| Recruiting | 2 | 150 | US | AB-1002, Gene Therapy, NAN-101 | Asklepios Biopharmaceutical, Inc. | Congestive Heart Failure | 10/26 | 12/30 | | |
| Completed | N/A | 42 | Canada, US | Interpersonal Counseling for University Counseling Centers, IPC-C | Johns Hopkins University, Amherst College, University of Toronto | Depression | 08/23 | 08/23 | | |
NCT06258447: CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction |
|
|
| Recruiting | N/A | 250 | US | Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system | BioCardia, Inc. | Ischemic Heart Failure | 04/27 | 04/29 | | |
| Recruiting | N/A | 372 | US | Aquadex Smartflow® System, IV Loop Diuretics | Nuwellis, Inc. | Heart Failure (for Example, Fluid Overload) | 07/25 | 10/25 | | |
| Saggar, Rajan |
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Ralinepag, APD811, Placebo | United Therapeutics | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 12/24 | 12/24 | | |
| Terminated | 3 | 186 | Europe, Canada, US, RoW | AV-101 | Aerovate Therapeutics, Aerovate Therapeutics Inc | Pulmonary Arterial Hypertension | 08/24 | 08/24 | | |
| Terminated | 2/3 | 202 | Europe, Canada, US, RoW | AV-101, Placebo | Aerovate Therapeutics, Aerovate Therapeutics, Inc. | Pulmonary Arterial Hypertension | 08/24 | 08/24 | | |
| Completed | 2 | 108 | Europe, Canada, US, RoW | rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo | Altavant Sciences GmbH | Pulmonary Arterial Hypertension | 06/23 | 08/23 | | |
ASCENT, NCT06129240: An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH |
|
|
| Recruiting | N/A | 60 | US | LIQ861 | Liquidia Technologies, Inc. | Pulmonary Hypertension, Interstitial Lung Disease | 07/26 | 10/26 | | |
| Recruiting | N/A | 1500 | Europe, US, RoW | assessment of pulmonary hemodynamics during exercise by right heart catheterization | Medical University of Graz, European Respiratory Society | Pulmonary Circulation Diseases | 12/29 | 12/29 | | |
ASPIRE PH, NCT04555161: Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System |
|
|
| Recruiting | N/A | 30 | US | Aria CV Pulmonary Hypertension System, Aria CV PH System | Aria CV, Inc | Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction | 10/25 | 10/26 | | |
| Adeoye, Opeolu |
| Active, not recruiting | 3 | 514 | US | Argatroban, Eptifibatide, Placebo | Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS) | Acute Ischemic Stroke | 12/23 | 04/25 | | |
| Enrolling by invitation | N/A | 2000 | US | BE FAST Educational video, F.A.S.T. Educational Video | American Heart Association | Stroke, Acute | 07/24 | 07/24 | | |
| Henry, Timothy D |
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure |
|
|
| Recruiting | 2 | 150 | US | AB-1002, Gene Therapy, NAN-101 | Asklepios Biopharmaceutical, Inc. | Congestive Heart Failure | 10/26 | 12/30 | | |
| Recruiting | 1 | 12 | US | 3 x 10e13vg NAN-101 | Asklepios Biopharmaceutical, Inc. | Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases, Heart Failure, Systolic, Heart Failure，Congestive, Heart Arrhythmia, Heart Failure, Diastolic, Heart; Complications | 12/26 | 12/26 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
| Recruiting | N/A | 500 | US | Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire, Acetylcholine Provocation | Yale University, Abbott | Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography | 12/32 | 12/32 | | |
| Recruiting | N/A | 70 | US | | Gentuity, LLC | Coronary Artery Disease | 12/25 | 07/26 | | |
| Smith, Timothy W |
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 780 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Antihyperglycemic medication | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 11/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity |
|
|
| Recruiting | 3 | 800 | Europe, US, RoW | Retatrutide, LY3437943, Tirzepatide, LY3298176 | Eli Lilly and Company | Obesity | 04/27 | 04/27 | | |
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities |
|
|
| Completed | 3 | 751 | US | Tirzepatide, LY3298176, Semaglutide | Eli Lilly and Company | Obesity, Overweight | 11/24 | 11/24 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
| Active, not recruiting | 3 | 2300 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight |
|
|
| Active, not recruiting | 3 | 1000 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 05/26 | 05/26 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Active, not recruiting | 3 | 14013 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 04/29 | 04/29 | | |
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention |
|
|
| Terminated | 2/3 | 538 | US | BHV-3500 (zavegepant), Placebo | Pfizer | Migraine | 03/24 | 03/24 | | |
OA05, NCT05620563: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain |
|
|
| Completed | 2 | 147 | US | LY3857210, Placebo | Eli Lilly and Company | Osteoarthritis | 06/23 | 06/23 | | |
NCT05630196: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain |
|
|
| Completed | 2 | 138 | US | LY3857210, Placebo | Eli Lilly and Company | Chronic Low-back Pain | 06/23 | 06/23 | | |
NCT05620576: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05). |
|
|
| Completed | 2 | 131 | US | LY3857210, Placebo | Eli Lilly and Company | Diabetic Peripheral Neuropathic Pain | 07/23 | 08/23 | | |
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight |
|
|
| Recruiting | 2 | 1040 | US, RoW | LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492 | Eli Lilly and Company | Obesity, Overweight | 06/26 | 09/26 | | |
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight |
|
|
| Recruiting | 2 | 250 | US, RoW | LY3841136, Placebo | Eli Lilly and Company | Obesity, Overweight and Obesity | 06/25 | 09/25 | | |
